We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+6.85%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$189M
AUM Growth
+$25.9M
Cap. Flow
+$19M
Cap. Flow %
10.03%
Top 10 Hldgs %
53.85%
Holding
93
New
27
Increased
23
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$2.5M
2
TPB icon
Turning Point Brands
TPB
+$1.88M
3
AMGN icon
Amgen
AMGN
+$1.6M
4
JNJ icon
Johnson & Johnson
JNJ
+$987K
5
IWM icon
iShares Russell 2000 ETF
IWM
+$588K

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$3.59M
2
BIIB icon
Biogen
BIIB
+$1.36M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$1.08M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$713K
5
NEM icon
Newmont
NEM
+$368K

Sector Composition

Rank Sector Weight
1 Healthcare 35.09%
2 Technology 14.46%
3 Communication Services 6.26%
4 Consumer Discretionary 3.14%
5 Energy 2.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
META icon
51
Meta Platforms (Facebook)
META
$1.42T
$631K 0.33%
2,200
– –
IWM icon
52
iShares Russell 2000 ETF
IWM
$79.8B
$618K 0.33%
+3,300
New +$588K
INTC icon
53
Intel
INTC
$455B
$585K 0.31%
17,500
– –
BUR icon
54
Burford Capital
BUR
$903M
$572K 0.3%
47,000
+3,000
+7% +$38.8K
MU icon
55
CALL
Micron Technology
MU
$930B
$536K 0.28%
+8,500
New +$546K
ORCL icon
56
PUT
Oracle
ORCL
$374B
$536K 0.28%
+4,500
New +$465K
SNY icon
57
Sanofi
SNY
$103B
$534K 0.28%
9,900
– –
BA icon
58
Boeing
BA
$171B
$528K 0.28%
2,500
+250
+11% +$51.9K
EOG icon
59
EOG Resources
EOG
$79.2B
$521K 0.28%
4,550
+2,150
+90% +$246K
EEM icon
60
iShares MSCI Emerging Markets ETF
EEM
$28.8B
$495K 0.26%
12,500
– –
EVO icon
61
Evotec
EVO
$679M
$483K 0.26%
42,738
+30,350
+245% +$324K
ALT icon
62
CALL
Altimmune
ALT
$552M
$473K 0.25%
134,000
– –
VRDN icon
63
Viridian Therapeutics
VRDN
$2.09B
$452K 0.24%
+19,000
New +$487K
ALT icon
64
Altimmune
ALT
$552M
$424K 0.22%
119,975
+43,000
+56% +$193K
WOLF icon
65
Wolfspeed
WOLF
$1.23B
$389K 0.21%
+7,000
New +$357K
IMPL
66
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$386K 0.2%
303,605
-79,543
-21% -$121K
DOCU
67
CALL
DocuSign
DOCU
$10.5B
$383K 0.2%
+7,500
New +$397K
C icon
68
Citigroup
C
$222B
$334K 0.18%
+7,250
New +$340K
BABA icon
69
CALL
Alibaba
BABA
$293B
$333K 0.18%
+4,000
New +$350K
LRCX icon
70
Lam Research
LRCX
$367B
$321K 0.17%
+5,000
New +$282K
SPOT icon
71
Spotify
SPOT
$103B
$321K 0.17%
2,000
– –
GDX icon
72
VanEck Gold Miners ETF
GDX
$22.7B
$316K 0.17%
+10,500
New +$342K
ALNY icon
73
Alnylam Pharmaceuticals
ALNY
$27.5B
$304K 0.16%
1,600
+200
+14% +$39.7K
TEVA icon
74
Teva Pharmaceuticals
TEVA
$40.8B
$294K 0.16%
+39,000
New +$316K
PYPL icon
75
PayPal
PYPL
$48.9B
$267K 0.14%
+4,000
New +$273K
1 2
3
4

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return
LWMNY
Landmark Wealth Management (New York) Melville, New York $373M AUM 12.01% 1-Year Est. Return

DCF Advisers's Q2 2023 Portfolio in Review

As of Q2 2023, DCF Advisers held 93 positions worth $189M, up 16% from $163M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

DCF Advisers deployed $19M of net new capital in Q2 2023, opening 27 new positions and adding to 23 existing holdings. Its largest new stake was Zimmer Biomet: 18,397 shares worth $2.68M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 40% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was AbbVie, an estimated $3.59M trimmed.

  • DCF Advisers's largest Q2 2023 buy was Zimmer Biomet: 18,397 shares worth $2.68M.
  • DCF Advisers added most to Amgen in Q2 2023, an estimated $1.6M increase.
  • DCF Advisers's biggest Q2 2023 reduction was AbbVie, cutting an estimated $3.59M.
  • DCF Advisers fully exited Biogen in Q2 2023, selling an estimated $1.36M.
  • DCF Advisers's ten largest holdings make up 54% of its $189M portfolio in Q2 2023.
  • DCF Advisers opened 27 new positions and closed 5 in Q2 2023.
  • DCF Advisers's portfolio value rose 16% quarter-over-quarter to $189M.

Based on DCF Advisers's 13F filing for Q2 2023, filed 9 Aug 2023.